Detection and Prevention of Cervical Cancer
HPV TESTING CENTRE provides essential guidelines and recommendations for cervical cancer screening. Understanding the latest recommendations is crucial for maintaining optimal cervical health. It is crucial to gain information about screening intervals, starting age, and other critical factors in cervical cancer prevention.
Screening Age Recommendations
Screening Under Age 21
The Ontario Cervical Screening Program advises against cervical screening for patients under 21. This recommendation is based on the fact that cervical cancer is sporadic in this age group and that most abnormalities resolve on their own without treatment.
Screening Under Age 25
Healthcare providers are encouraged to consider delaying screening until age 25, except for immunocompromised individuals. This approach aims to balance the benefits of early detection with the potential harms of over-screening.
Triennial vs. Annual Screening
Why Triennial PAP Screening (Every 3 Years)
Triennial screening, or screening every three years, is recommended for cervical cancer screening for several reasons:
Alignment with Natural History: Triennial screening aligns with the natural history of cervical cancer. Cervical cancer typically develops over many years, and screening every three years allows for the timely detection of abnormalities while minimizing unnecessary interventions.
Lack of Evidence for Annual Screening: There is no evidence to recommend that annual screening is superior to triennial screening in reducing the incidence or mortality of cervical cancer. Annual screening may lead to increased harm without significantly improving benefits.
Balancing Benefits and Harms: More frequent screening intervals increase the risk of harm, such as false-positive results, unnecessary follow-up procedures, and psychological distress, without a proportional benefit increase.
Safety and Effectiveness: Screening every three years is safe and effective. Pre-malignant cervical changes develop slowly, and clinically significant abnormalities can be detected within a three-year interval. Timely detection allows for prompt treatment, preventing the progression of cervical cancer.
When Should Cervical Screening Begin
Ontario Health encourages starting cervical screening at age 25. This recommendation is based on several factors:
Limited Benefit for Individuals Under 25: Evidence suggests that the benefits of cervical screening for individuals under 25 are limited. Cervical cancer is rare in this age group, and abnormalities detected are often transient and resolve spontaneously without treatment.
Evidence-Based Practice: The decision to initiate screening at age 25 is supported by evidence-based guidelines and aims to optimize the balance between the benefits and harms of screening.
Screening Beyond Age 70
No evidence supports routine cervical screening over the age of 70 for individuals with new sexual partners. Healthcare providers should carefully weigh the risks and benefits and make individualized recommendations based on the patient's overall health status and preferences. Continuing cervical screening beyond age 70 is recommended if:
No Three or More Negative Pap Tests in the Previous Ten Years: If an individual has not had three or more negative Pap tests in the previous ten years, it is advisable to continue screening to ensure the ongoing detection of any potential abnormalities.
Adequate Negative Screen History Before Age 70: Individuals with a history of negative screening results before reaching 70 should continue with screening, as long as they meet the other criteria.
Frequent Screening Exceptions
Annual Cervical Cytology Screening
Immunocompromised Patients: Individuals with compromised immune systems, such as those living with HIV/AIDS or on long-term immunosuppressants, are recommended to undergo annual cervical screening.
Patients Previously Treated in Colposcopy with HPV-Positive Results or ASCUS/LSIL Cytology: Patients who have undergone treatment in colposcopy due to HPV-positive results or abnormal cytology (ASCUS/LSIL) are advised to undergo annual cervical screening to monitor for recurrence or persistence of abnormal changes.
Immunocompromised Populations Requiring Annual Screening
The Ontario Cervical Screening Program defines the following groups needing annual cervical screening:
People Living with Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS).
Individuals on Continuous or Frequent Immunosuppressive Medications.
Organ Transplant Recipients (solid organ or allogeneic stem cell transplants).
People with Systemic Lupus Erythematosus (SLE), regardless of immunosuppressant treatment.
Individuals with Congenital (Primary) Immunodeficiency.
Patients Requesting Annual Screening
Evidence supports a 3-year screening interval as safe and effective.
Annual screening for average-risk patients isn't better than screening every 3 years.
Potential harms of more frequent screening include false positives, overtreatment, discomfort, and embarrassment.
Annual screening doesn't provide extra protection against cervical cancer.
Exceptions exist for exceptional circumstances (e.g., some post-colposcopy patients and immunocompromised individuals).
HPV Testing
- HPV is a common sexually transmitted infection.
- It can cause genital warts and is associated with various cancers, including cervical, anal, and oropharyngeal cancers.
- High-risk HPV strains (such as HPV 16 and 18) are linked to cervical cancer.
- Pap Smear (Pap Test): Historically used for cervical cancer screening.
- Detects abnormal cervical cells.
- Limited sensitivity and specificity.
- HPV Testing: More accurate than Pap smear alone.
- Identifies high-risk HPV strains.
- Used for primary cervical cancer screening.
- Recommended for women aged 30 and older.
- Can be done alone (standalone HPV test) or in combination with Pap smear (co-testing).
- Negative HPV Test: Reassurance and regular screening.
- Positive HPV Test: Further risk assessment based on specific HPV type.
- Risk-Based Management: Combines current test results with past screening history.
- Determines the need for surveillance, colposcopy, or treatment.
- Colposcopy: Visual examination of the cervix using a colposcope.
- Biopsy if abnormal areas are detected.
- Treatment: Excisional procedures (LEEP, cone biopsy) for precancerous lesions.
- Expedited treatment without colposcopic biopsy for certain cases (e.g., high-grade squamous intraepithelial lesion with HPV 16 positivity).
HPV Self Testing
Self-sampling for cervical cancer screening offers several benefits:
Increased Accessibility: Individuals can screen themselves anywhere they feel safe and comfortable, such as at home.
Alternative to Pap Tests: Self-sampling provides an alternative to the traditional Pap test for regular cervix screening.
Effective Detection: The test detects human papillomavirus (HPV), the virus that causes cervical cancer, allowing for early prevention of cancer development.
Order an HPV Kit for Self Testing
Ordering an HPV kit for self-testing has never been easier. Simply visit the provided links to access HPV testing kits from reputable sources.
How to Perform Self-Sampling
- 1.
Request a Kit: If you are eligible and due for screening, request a self-screening kit online or by phone. The kit will arrive in a plain, unmarked envelope within approximately 2 weeks.
- 2.
Collect the Sample: Follow the instructions inside the kit (available in multiple languages). Use a small swab (similar to a Q-tip) to collect a sample from your vagina. You can do this at home or, if you prefer, at a healthcare provider’s office.
- 3.
Return the Kit: Drop off your completed kit at your nearest post office or post box the same day you collect your sample.
- 4.
Get Results: You and a healthcare provider will receive results in 4–6 weeks. You can also view your results online through Health Gateway.
Actions Based on Results
Negative Result (No HPV Detected): No further action is needed. The next screening may be due in five years.
Positive Result (HPV Detected): Follow-up visits and additional tests may be necessary. Consult a healthcare provider for further evaluation. Treatment may be required if abnormal cell changes are found.
Note: Remember, self-sampling is easy, painless, and free of charge. It provides accurate results and empowers individuals to take control of their cervical health.
HPV Physician Testing vs. Self-Testing: a Comparative Perspective
Self-sampling for HPV testing has become increasingly popular due to its convenience and accessibility, especially with the incorporation of HPV primary testing into cervical cancer screening programs worldwide. Let's compare the value of physician testing (clinician-collected samples) with self-testing:
Accuracy
Self-Sampling: Studies consistently show that self-sampling is as accurate as physician-collected samples in detecting high-grade cervical intraepithelial neoplasia (CIN) or cervical cancers.
Physician Testing: Clinician-collected samples yield comparable results to self-sampling.
Sensitivity
Self-Sampling: High sensitivity for detecting CIN2+ or CIN3+ lesions.
Physician Testing: Similar sensitivity to self-sampling.
Positive Predictive Value (PPV)
Self-Sampling: PPV for CIN2+ is around 28%, and for HPV16/18, it’s approximately 43.7%.
Physician Testing: Comparable PPV values.
Negative Predictive Value (NPV)
Self-Sampling: NPV for CIN2+ is approximately 96.4%.
Physician Testing: Similar NPV values.
Benefits of Self-Sampling
Increased Coverage: Self-sampling enhances participation by allowing women to collect samples at home.
Alternative to Pap Tests: It complements traditional screening methods.
Challenges of Self-Sampling
Low Return Rate: Some individuals may not complete or return self-sampling kits. Strategies to mitigate this include sending introductory letters, educating individuals on proper self-collection, and community campaigns.
Privacy and Packaging Concerns: Mailed self-collection kits should address privacy and packaging issues. Kits can be packaged discreetly, and maintaining up-to-date addresses in the screening registry is crucial.
Over-Screening Risk: Ensuring self-collected results are linked to the screening registry helps prevent unnecessary repeat testing.
Self-Sampling: A Promising Approach to Cervical Cancer Screening
In summary, self-sampling has the potential to increase coverage and improve cervical cancer screening outcomes. Both approaches are valuable, and the choice depends on individual preferences and program implementation.
Resources for Further Reading
Get Quick Answers in Our FAQs Section
Please take a moment to review our FAQs for more information. If you have any questions, our FAQs provide helpful answers.